Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 461-467

  Vose, Julie M ^a   Bierman, Philip J ^a   Enke, Charles ^a   Hankins, Jordan ^a   Bociek, Gregory ^a   Lynch, James C ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; MITOXANTRONE; NAVELBINE; PARACETAMOL; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE; ANTINEOPLASTIC AGENT; BEAM REGIMEN; CD20 ANTIGEN; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; KIDNEY FAILURE; LUNG EDEMA; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; TREATMENT RESPONSE; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MELPHALAN; MIDDLE AGED; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 14544292501     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.117     Document Type: Article

References (32)

1. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
2. Shipp MA, Harrington DP, Klatt MM, et al: Identification of major prognostic subgroups of patients with large cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104:757-765, 1986
3. Gordon LI, Harrington D, Andersen J, et al: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327:1342-1349, 1992
4. Velasquez WS, Lew D, Grogan TM, et al: Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 21:1996-2003, 2003
5. B. Horning SJ: Treatment approaches to the low-grade lymphomas. Blood 83:881-884, 1994
6. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
7. Philip T, Armitage JO, Spitzer G, et al: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults and intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
8. Vose JM, Zhang MJ, Bowlings PA, et al: Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the autologous blood and marrow transplant registry. J Clin Oncol 19:406-413, 2001
9. Sutcliffe SB, Gospodarowicz MK, Bush RS, et al: Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol 4:211-223, 1985
10. Mac Manus MP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282-1290, 1996
11. Horning SJ, Negrin RS, Chao JC, et al: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552-2558, 1994
12. Gutierrez-Delgado F, Maloney D, Press O, et al: Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant 28:455-461, 2001
13. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755, 2003
14. Horwitz SM, Negrin RS, Blume KG, et al: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma. Blood 103:777-783, 2004
15. Press OW, Eary J, Appelbaum FR, et al: Radiolabeled antibody therapy of B cell lymphomas with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
16. Press OW, Eary JF, Appelbaum FR, et al: A phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340, 1995
17. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000
18. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000
19. Kaminiski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001
20. Loevinger R1 Budinger TF, Watson EE: MIRD Primer for Absorbed Dose Calculations. Reston, VA, The Society of Nuclear Medicine Inc, 1988
21. Siegel JA: Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: Outpatient iodine-131 Anti-B1 therapy. J Nucl Med 39:28s-33S, 1998
22. National Cancer Institute: NCI toxicity criteria. http://ctep.cancer.gov
23. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Sonis ST, Oster G, Fuchs H, et al: Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 19:2201-2205, 2001
26. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994
27. Metayer C, Curtis RE, Vose J, et al: Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study. Blood 101:2015-2023, 2003
28. Stiff P, Dahlberg S, Forman SJ, et al: Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens-A Southwest Oncology Group trial. J Clin Oncol 16:48-55, 1998
29. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
30. Coleman M, Kaminski MS, Knox SJ, et al: The Bexxar Therapeutic regimen (tositumomab and iodine I 131 tositumomab) produced durable complete remissions in heavily pretreated patients with non-Hodgkin's lymphoma (NHL), rituximab-relapsed/refractory disease, and rituximab-naïve disease. Blood 102:29, 2003 (abstr 89a)
31. Lui SY, Eary JF, Petersdorf SH, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem cell rescue. J Clin Oncol 16:3270-3278, 1998
32. Nademanee A, Molina A, Forman SJ, et al: A phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (Cy) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood 100:182, 2002 (abstr 679a)